Lonza and Onava Form Biotech AI Partnership
The two companies are collaborating to refine predictive biologics models using advanced gene expression technology.
Updated on Oct. 20, 2026 in Biotech
Live Poll
Do you believe AI-driven drug discovery will successfully result in better and more affordable medicines?
Lonza and Onava have entered a Research Evaluation Agreement to integrate Lonza's GS Gene Expression System and GS Ori-Go vectors into Onava's AI-native drug discovery platform. The partnership aims to generate high-quality experimental data to train and improve Onava's predictive models for therapeutic development.
Why it matters
Onava requires consistent, experimentally grounded data to bridge the gap between computational insights and physical biological results. By incorporating Lonza's established technology, the firm hopes to translate AI predictions into viable therapeutic candidates with greater efficiency.
Onava will integrate the GS Gene Expression System platform and GS Ori-Go vectors into its discovery workflow. This technical pairing connects computational AI predictions with concrete experimental data generation.
The players
Lonza
Lonza is a global manufacturing and development partner for the pharmaceutical, biotech, and nutrition markets.
Onava
Onava is a biotech company specializing in AI-native platforms for the discovery of new biologics.
The details
Onava plans to leverage the technology across its internal research programs and future external partnerships. Lonza will provide ongoing support for cell line and process development as Onava's research candidates advance toward therapeutic applications.
Timeline
October 20, 2026: Lonza and Onava formally announced the new research collaboration.
The Tech Race
The integration of the GS Gene Expression System into AI workflows highlights an industry-wide effort to reduce the high failure rates in early-stage drug discovery. By replacing traditional, fragmented testing with automated, data-rich experimental feedback, companies are accelerating the transition from digital prediction to physical medicine.
While this partnership is a research-level development, its success could shorten the time required for new biologics to move from the digital discovery phase into clinical trials. Users and patients may eventually see a wider variety of specialized treatments reach the market faster as AI models become more accurate.
The takeaway
This agreement underscores a growing industry trend where AI-native firms partner with legacy infrastructure providers to ground theoretical models in biological reality. It serves as a reminder that even the most advanced predictive algorithms are only as effective as the experimental data used to train them.
Further reading
For more on how companies are integrating artificial intelligence into the research process, explore the Biotech section.
Live Poll
Do you believe AI-driven drug discovery will successfully result in better and more affordable medicines?
